IL126832A0 - Biphenylsulfonamide matrix metalloproteinase inhibitors - Google Patents
Biphenylsulfonamide matrix metalloproteinase inhibitorsInfo
- Publication number
- IL126832A0 IL126832A0 IL12683297A IL12683297A IL126832A0 IL 126832 A0 IL126832 A0 IL 126832A0 IL 12683297 A IL12683297 A IL 12683297A IL 12683297 A IL12683297 A IL 12683297A IL 126832 A0 IL126832 A0 IL 126832A0
- Authority
- IL
- Israel
- Prior art keywords
- matrix metalloproteinase
- metalloproteinase inhibitors
- alkyl
- biphenylsulfonamide
- biphenylsulfonamide matrix
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1746096P | 1996-05-17 | 1996-05-17 | |
| PCT/US1997/006801 WO1997044315A1 (en) | 1996-05-17 | 1997-04-24 | Biphenylsulfonamide matrix metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL126832A0 true IL126832A0 (en) | 1999-08-17 |
Family
ID=21782716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12683297A IL126832A0 (en) | 1996-05-17 | 1997-04-24 | Biphenylsulfonamide matrix metalloproteinase inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0901466B1 (et) |
| JP (1) | JP2000511175A (et) |
| KR (1) | KR20000011095A (et) |
| CN (1) | CN1077885C (et) |
| AT (1) | ATE207891T1 (et) |
| BG (1) | BG63940B1 (et) |
| BR (1) | BR9710841A (et) |
| CA (1) | CA2253342A1 (et) |
| CZ (1) | CZ294063B6 (et) |
| DE (1) | DE69707865T2 (et) |
| DK (1) | DK0901466T3 (et) |
| EA (1) | EA001561B1 (et) |
| EE (1) | EE03965B1 (et) |
| ES (1) | ES2167733T3 (et) |
| HK (1) | HK1019585A1 (et) |
| IL (1) | IL126832A0 (et) |
| NO (1) | NO312510B1 (et) |
| NZ (1) | NZ332711A (et) |
| PL (1) | PL186416B1 (et) |
| PT (1) | PT901466E (et) |
| SK (1) | SK282863B6 (et) |
| WO (1) | WO1997044315A1 (et) |
| ZA (1) | ZA974223B (et) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU690703B2 (en) * | 1994-06-22 | 1998-04-30 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| US6124333A (en) * | 1995-06-22 | 2000-09-26 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| KR20000057444A (ko) * | 1996-12-09 | 2000-09-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 심기능부전 및 심실확장의 치료 및 예방 방법 |
| EP1366765A1 (en) * | 1996-12-17 | 2003-12-03 | Warner-Lambert Company Llc | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing |
| EP0946166B1 (en) | 1996-12-17 | 2004-02-18 | Warner-Lambert Company LLC | Use of matrix metalloproteinase inhibitors for promoting wound healing |
| GB9706255D0 (en) | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
| DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| EP1398027B1 (en) * | 1997-07-22 | 2007-01-10 | Shionogi & Co., Ltd. | Use of matrix metalloproteinase inhibitors for treating or preventing glomerulopathy |
| EP1047450B1 (en) * | 1997-12-23 | 2002-10-02 | Warner-Lambert Company | Ace inhibitor-mmp inhibitor combinations |
| HUP0101176A3 (en) * | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
| US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| WO1999047138A1 (en) * | 1998-03-17 | 1999-09-23 | Warner-Lambert Company | Statin-matrix metalloproteinase inhibitor combinations |
| EP0967201A1 (en) * | 1998-05-20 | 1999-12-29 | Roche Diagnostics GmbH | Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors |
| BR9912085A (pt) * | 1998-07-16 | 2001-04-10 | Aventis Pharma Gmbh | Derivados de ácido fosfìnico e ácido fosfÈnico como medicamentos |
| CZ2001126A3 (cs) * | 1998-07-21 | 2002-01-16 | Warner-Lambert Company | Společné účinky ACAT a MMP inhibitorů při léčbě aterosklerotických lézí |
| DE19851184A1 (de) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
| CN1347411A (zh) * | 1999-04-19 | 2002-05-01 | 盐野义制药株式会社 | 含有噁二唑环的磺酰胺衍生物 |
| GB9918684D0 (en) | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
| PL211888B1 (pl) | 1999-11-26 | 2012-07-31 | Shionogi & Co | Związek będący antagonistą NPY Y5 oraz kompozycja farmaceutyczna zawierająca taki związek |
| CN1273456C (zh) * | 2000-09-29 | 2006-09-06 | 盐野义制药株式会社 | 噻唑和噁唑衍生物 |
| GB0103303D0 (en) | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
| MXPA01013326A (es) * | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz. |
| WO2003035610A1 (fr) * | 2001-10-26 | 2003-05-01 | Shionogi & Co., Ltd. | Derive de sulfonamide a effet inhibiteur sur les mmp |
| GB0314488D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
| EP1689716A1 (en) * | 2003-12-04 | 2006-08-16 | Wyeth | Biaryl sulfonamides and methods for using same |
| PL1735274T3 (pl) | 2004-03-22 | 2010-05-31 | Southern Res Inst | Niepeptydowe inhibitory metaloproteinaz macierzy zewnątrzkomórkowej |
| CN101279956B (zh) * | 2008-04-25 | 2011-06-15 | 南昌大学 | 一种基质金属蛋白酶抑制剂及合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| AU690703B2 (en) * | 1994-06-22 | 1998-04-30 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
-
1997
- 1997-04-24 PT PT97918788T patent/PT901466E/pt unknown
- 1997-04-24 EA EA199800988A patent/EA001561B1/ru not_active IP Right Cessation
- 1997-04-24 WO PCT/US1997/006801 patent/WO1997044315A1/en not_active Application Discontinuation
- 1997-04-24 EP EP97918788A patent/EP0901466B1/en not_active Expired - Lifetime
- 1997-04-24 SK SK1577-98A patent/SK282863B6/sk unknown
- 1997-04-24 CN CN97194719A patent/CN1077885C/zh not_active Expired - Fee Related
- 1997-04-24 DE DE69707865T patent/DE69707865T2/de not_active Expired - Fee Related
- 1997-04-24 NZ NZ332711A patent/NZ332711A/en unknown
- 1997-04-24 DK DK97918788T patent/DK0901466T3/da active
- 1997-04-24 EE EE9800397A patent/EE03965B1/et not_active IP Right Cessation
- 1997-04-24 AT AT97918788T patent/ATE207891T1/de not_active IP Right Cessation
- 1997-04-24 IL IL12683297A patent/IL126832A0/xx unknown
- 1997-04-24 KR KR1019980709253A patent/KR20000011095A/ko not_active Application Discontinuation
- 1997-04-24 JP JP09542377A patent/JP2000511175A/ja not_active Abandoned
- 1997-04-24 BR BR9710841A patent/BR9710841A/pt not_active IP Right Cessation
- 1997-04-24 CA CA002253342A patent/CA2253342A1/en not_active Abandoned
- 1997-04-24 PL PL97329929A patent/PL186416B1/pl not_active IP Right Cessation
- 1997-04-24 CZ CZ19983668A patent/CZ294063B6/cs not_active IP Right Cessation
- 1997-04-24 ES ES97918788T patent/ES2167733T3/es not_active Expired - Lifetime
- 1997-05-15 ZA ZA9704223A patent/ZA974223B/xx unknown
-
1998
- 1998-11-12 BG BG102918A patent/BG63940B1/bg unknown
- 1998-11-16 NO NO19985326A patent/NO312510B1/no not_active IP Right Cessation
-
1999
- 1999-10-27 HK HK99104791A patent/HK1019585A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BG63940B1 (bg) | 2003-07-31 |
| CZ294063B6 (cs) | 2004-09-15 |
| DK0901466T3 (da) | 2002-02-18 |
| HK1019585A1 (en) | 2000-02-18 |
| AU713286B2 (en) | 1999-11-25 |
| EE9800397A (et) | 1999-06-15 |
| NO985326L (no) | 1999-01-14 |
| EE03965B1 (et) | 2003-02-17 |
| PL186416B1 (pl) | 2004-01-30 |
| BR9710841A (pt) | 1999-08-17 |
| AU2680397A (en) | 1997-12-09 |
| ES2167733T3 (es) | 2002-05-16 |
| CN1077885C (zh) | 2002-01-16 |
| EP0901466A1 (en) | 1999-03-17 |
| CA2253342A1 (en) | 1997-11-27 |
| NO312510B1 (no) | 2002-05-21 |
| EP0901466B1 (en) | 2001-10-31 |
| WO1997044315A1 (en) | 1997-11-27 |
| PL329929A1 (en) | 1999-04-26 |
| BG102918A (en) | 1999-09-30 |
| SK282863B6 (sk) | 2002-12-03 |
| EA199800988A1 (ru) | 1999-04-29 |
| KR20000011095A (ko) | 2000-02-25 |
| CN1219166A (zh) | 1999-06-09 |
| JP2000511175A (ja) | 2000-08-29 |
| NO985326D0 (no) | 1998-11-16 |
| PT901466E (pt) | 2002-04-29 |
| DE69707865D1 (de) | 2001-12-06 |
| SK157798A3 (en) | 1999-04-13 |
| ZA974223B (en) | 1997-12-10 |
| ATE207891T1 (de) | 2001-11-15 |
| DE69707865T2 (de) | 2002-05-02 |
| CZ366898A3 (cs) | 1999-02-17 |
| NZ332711A (en) | 2000-06-23 |
| EA001561B1 (ru) | 2001-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA974223B (en) | Biphenylsulfonamide matrix metalloproteinase inhibitors. | |
| AU6894800A (en) | Caspase inhibitors and uses thereof | |
| GB9801690D0 (en) | Therapeutic agents | |
| WO2003024448A3 (en) | Inhibitors of histone deacetylase | |
| NZ332762A (en) | Isobutylgaba and its derivatives for the treatment of pain | |
| HK1022468A1 (en) | Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors. | |
| AU2001248701A1 (en) | Inhibitors of histone deacetylase | |
| PL312196A1 (en) | Heterocyclic phenyl compounds as inhibitors of cyclooxygenase-2 | |
| AU2483000A (en) | Treatment of asthma with mek inhibitors | |
| NZ285846A (en) | Arylsulphonamido-substituted hydroxamic acids and preparation and medicaments useful for inhibiting metalloproteinases | |
| PL343495A1 (en) | Heterocyclically substituted amides used as calpain inhibitors | |
| NZ333550A (en) | Matrix metalloproteinase inhibitors for inhibiting the release of TNF | |
| AU1314300A (en) | Methods and compositions for inhibiting polymerization of ethylenically unsaturated hydrocarbons | |
| CA2266759A1 (en) | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | |
| AU9066498A (en) | Substituted 6-alkylphenanthridines | |
| CY2225B1 (en) | Organic compounds | |
| AU3729397A (en) | Butyric acid matrix metalloproteinase inhibitors | |
| GB2324091A (en) | Metalloproteinase inhibitors | |
| HK1024872A1 (en) | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia | |
| ES2173634T3 (es) | Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf. |